PharmAust and LUMC will now progress the antiviral development program to testing in human cells.
MPLS shows antiviral activity reaching 95%.
GMP-quality MPL production for human clinical trials has commenced at Syngene International Ltd (India).
PAA clinical development plans remains unchanged.
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity, page-11
-
- There are more pages in this discussion • 722 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.005(2.86%) |
Mkt cap ! $87.51M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.3¢ | 17.5¢ | $205.5K | 1.150M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 55777 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 56756 | 2 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |